Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial
Dominique Baeten(University of Amsterdam), Xenofon Baraliakos(Rheumazentrum Ruhrgebiet), Jürgen Braun(Rheumazentrum Ruhrgebiet), Joachim Sieper(Charité - Universitätsmedizin Berlin), Paul Emery(Leeds Teaching Hospitals NHS Trust), Désirée van der Heijde(Leiden University Medical Center), Iain B. McInnes(University of Glasgow), Jacob M. van Laar(Newcastle University), Robert Landewé(Atrium Medisch Centrum Parkstad), B P Wordsworth(National Institute for Health Research), J. Wollenhaupt(Schön Klinik Hamburg Eilbek), Herbert Kellner, Jacqueline E Paramarta(Academic Medical Center), Jiawei Wei(Novartis (China)), Arndt Brachat(Novartis (Switzerland)), Stephan Bek(Novartis (Switzerland)), Didier Laurent(Novartis (Switzerland)), Yali Li(Novartis (United States)), Ying A. Wang(Novartis (United States)), Arthur P. Bertolino(Novartis Institutes for BioMedical Research), Sandro Gsteiger(Novartis (Switzerland)), A. Wright(Novartis (Switzerland)), Wolfgang Hueber(Novartis (Switzerland))
Cited by 588
Abstract
Related Papers
A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis
Gerald G. Krueger, Richard G. Langley, Craig L. Leonardi et al.|New England Journal of Medicine|2007|784